# Glympse Bio

Glympse Bio is a Biotechnology Company based in Cambridge, United States.

## Overview

- **Organization type:** Biotechnology Company
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** Cambridge, MA, United States
- **Assets under management:** Undisclosed
- **Website:** glympsebio.com
- **LinkedIn:** https://www.linkedin.com/company/glympse-bio

## Regulatory record

- **Reports private funds:** No

## About

Glympse Bio is a biotechnology company founded in 2015 in Cambridge, Massachusetts. It develops technology using engineered diagnostic agents to monitor multiple human diseases. The company was acquired by Sunbird Bio in May 2023.

## Sectors

- Digital Health
- AI/ML

## Offices

- San Francisco, CA, United States

## Questions

### What technology does Glympse Bio use?

Glympse Bio's platform uses injectable nanoparticles that release synthetic biomarkers in response to disease-specific protease activity. These biomarkers are collected in urine and analyzed by a mass spectrometer, with machine learning algorithms interpreting the pattern to produce a disease signature.

### How is Glympse Bio funded?

Glympse Bio raised a $46 million Series A round in 2019 co-led by Andreessen Horowitz and Data Collective, with participation from Polaris Partners, Lifeforce Capital, and other venture firms (per the company's announcement, 2019). The company has not disclosed additional financing rounds.

### What diseases is Glympse Bio targeting?

Glympse Bio initially focused on non-alcoholic steatohepatitis (NASH), a form of liver disease. In 2021, the company announced a collaboration with the National Cancer Institute to expand into oncology applications. Its platform is designed to be programmable for multiple diseases, including fibrotic conditions and cancer.

### Is Glympse Bio a public company or privately held?

Glympse Bio is a privately held biotechnology company. It has not filed for an initial public offering and remains backed by venture capital investors.

### Who are the scientific founders of Glympse Bio?

Glympse Bio's technology originated from the laboratory of Sangeeta Bhatia, a professor at MIT and a core institute member at the Wyss Institute for Biologically Inspired Engineering. The company's diagnostic platform builds on research in synthetic biomarkers and nanoparticles published in peer-reviewed journals.

## Related profiles

- [XBTO Group](https://altss.com/profile/xbto-group)
- [Brookline Capital Markets](https://altss.com/profile/brookline-capital-markets)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/glympse-bio

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology